Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

1In vivo characterization of tau pathology using positron emission tomography (PET) constitutes a new frontier in Alzheimer’s disease (AD) research. It is expected that tau imaging agents will provide the means for staging disease progression as well as selecting patients appropriate for a given therapy, confirming the mechanism of action of pharmacological interventions affecting tau aggregates and monitoring treatment efficacy for AD.

218F-THK5351 is a quinoline-derivative tau imaging tracer with affinity to paired helical filaments (PHF), a typical tau aggregate present in neurofibrillary tangles (NFTs). 18F-THK5351 retention in the temporal lobes in vivo is able to distinguish AD patients from healthy individuals. However, 18F-THK5351 is also retained in the basal ganglia and other brain regions known to express negligible amounts of PHF, a phenomenon attributable to off-target binding, which raises concerns about the specificity of 18F-THK5351 for PHF. Rather than PHF, the basal ganglia typically express high concentrations of aminergic projections, neuroreceptors, and their degrading enzymes such as monoamine oxidase (MAO). As such, it is plausible to hypothesize that MAO-B (EC 1.4.3.4) constitutes a 18F-THK5351 off-target binding site, particularly given its previous reported affinity to quinolone derivatives. Furthermore, the presence of high concentrations of MAO-B in the human cortex demands a careful examination of the impact of MAO-B binding on 18F-THK5351 images.

3Selegiline is an irreversible MAO-B inhibitor utilized to enhance dopaminergic neurotransmission in Parkinson’s disease patients. Previous PET studies revealed a persistent MAO-B inhibition following a single administration of MAO-B inhibitors. As such, an acute selegiline challenge constitutes an interesting strategy to probe the contribution of brain MAO-B availability to the 18F-THK5351 uptake observed in patient populations.

4Here, in a longitudinal observation of patients with baseline and post-selegiline 18F-THK5351 PET scans, we tested the hypothesis that a reduction of MAO-B availability also reduces 18F-THK5351 uptake. We further tested this hypothesis in postmortem human tissue using autoradiography.

5Eight individuals (five mild cognitive impairment (MCI), two AD, and one progressive supranuclear palsy (PSP)) were recruited. All study participants were screened to exclude any underlying neuropsychiatric diseases such as depression and concomitant intake of MAO inhibitors. Study participants then underwent a Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The MCI, AD, and PSP diagnoses were made using the Petersen’s, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA), and the National Institute of Neurological Disorders and Stroke and the Society for PSP (NINDS-SPSP) criteria, respectively.

6All eight participants had baseline 18F-AZD4694 and 18F-THK5351 PET scans to quantify brain amyloid and PHF load, respectively. A second 18F-THK5351 scan was conducted 1 week later, 1 h after an oral dose of 10 mg selegiline. Participants were also invited to undergo an optional third 18F-THK5351 PET scan 10 days after the selegiline administration. Each 18F-THK5351 acquisition consisted of dynamic images (4 × 5 min) acquired at 50–70 min after intravenous bolus injection. The mean ± standard deviation injected radioactivity of 18F-THK5351 was 6.6 ± 0.3 mCi for the baseline scan, 6.7 ± 0.4 mCi for the post-selegiline scan, and 6.9 ± 0.4 mCi for the third scan. 18F-AZD4694 acquisition consisted of dynamic images (6 × 5 min) acquired at 40–70 min after intravenous bolus injection of 18F-AZD4694. The injected radioactivity of 18F-AZD4694 was 6.3 ± 0.3 mCi. A 6-min transmission scan was acquired at the end of each PET scan. All PET scans were performed using the Siemens High Resolution Research Tomograph (HRRT). A magnetic resonance imaging (MRI) anatomical scan was also performed for all patients using the 1.5 T Siemens Sonata scanner for co-registration purposes.

718F-THK5351 was synthesized according to a previously published paper, with an average specific activity of 24.3 Ci/μmol for the baseline scan, 19.2 Ci/μmol for the post-selegiline scan, and 13.5 Ci/μmol for the third scan. The average injected mass dose was 5.58 ng/kg for the baseline scan, compared with 6.68 ng/kg for the post-selegiline scan (P = 0.61, not significant), and 4.21 ng/kg for the third scan (P = 0.39, not significant). 18F-AZD4694 was synthesized using a modified synthesis procedure previously described, with an average specific activity of 6.1 Ci/μmol.

8T1-weighted MRI images were processed using the CIVET image processing pipeline for field distortions correction, and the PET images were processed using an established image processing pipeline. Briefly, using transformations obtained from PET native to MRI native space and the MRI native to the Montreal Neurological Institute (MNI) 152 space, the PET images were linearly registered and subsequently spatially normalized to the MNI 152 standardized space. The primary outcome measure was the standardized uptake value (SUV). SUVs were calculated using tissue radioactivity concentration data from 50 to 70 min following 18F-THK5351 injection, and 40 to 70 min following 18F-AZD4694 injection, normalized by body weight and injected radioactivity. The baseline and post-selegiline 18F-THK5351 SUVs in the cortical gray matter of the frontal, parietal, lateral temporal, and occipital lobes, hippocampus, cingulate gyri, basal ganglia, thalamus, and cerebellar cortex of each individual were measured. We then calculated the average percentage reduction of mean regional SUV in the post-selegiline scans. The 18F-THK5351 SUV ratio (SUVR) and 18F-AZD4694 SUVR were obtained using the cerebellar cortex and cerebellum as reference regions, respectively. The 18F-AZD4694 SUVR images were assessed by two independent experts (JPS and PRN) to visually classify the participants as amyloid-positive or amyloid-negative after full agreement was reached. In a clinical validation of 18F-AZD4694 using the cerebellum as the reference region, the SUVRs in AD patients varied between 2.10 and 2.88 across regions.

9In vitro autoradiography was performed on 14 postmortem brain sections (seven AD patients with a diagnosis confirmed by pathological assessment, and seven age-matched healthy controls) as previously described. In brief, baseline and R--deprenyl hydrochloride competition experiments were performed on adjacent brain sections (20 μm thickness). Prepared frozen brain tissues were warmed to room temperature, air-dried, and pre-incubated in a buffer saline solution (138 mM NaCl and 27 mM KCl, pH 7.4 adjusted by NaOH) and 1% bovine serum albumin for 20 min. Brain tissues were then air-dried and incubated with 18F-THK5351 (1.85 μCi) and the R--deprenyl hydrochloride challenge was performed at concentrations of 150 nM and 500 nM for 150 min. After the incubation, brain tissues were dipped three times in the buffer solution for 3 min each time, once in 4 °C water for 30 s, and dried under a stream of cool air. The brain sections were subsequently exposed to a radioluminographic imaging plate (Fujifilm BAS-MS2025) for 20 min and obtained using FUJIFILM BAS-5000. Activity in photostimulated luminescence units per mm2 was measured using Image Gauge 4.0 (Fujifilm) and the percentage of 18F-THK5351 total binding after R--deprenyl hydrochloride challenge was calculated.

10The statistical analysis was performed using GraphPad Prism Version 7.0b (GraphPad Software, La Jolla, California, USA; www.graphpad.com). The baseline and the post-selegiline regional 18F-THK5351 SUVs were compared using paired t test analyses. The Bonferroni correction was used to correct the aforementioned analyses for multiple comparisons.

11Baseline demographics and global 18F-AZD4694 SUVR of the study participants are summarized in Table 1. Patients 4, 5 and 8 are classified as amyloid-negative and patients 1, 2, 3, 6, and 7 are classified as amyloid-positive (Fig. 1).

12The 18F-THK5351 SUV map demonstrated an average of 36.7 to 51.8% regional uptake reduction in the post-selegiline scans from the baseline scans (Fig. 1). At baseline, the mean SUVs were highest in the basal ganglia (0.64 ± 0.11) followed by the thalamus (0.62 ± 0.14) (Fig. 2). In the post-selegiline scans, there were statistically significant regional SUV declines compared to the baseline scans. The SUV reduction was greatest in the thalamus (51.8%), followed by the basal ganglia (51.4%). MAO-B inhibition also reduced 18F-THK5351 SUVs in the cerebellar cortex (41.6%).

13In the three MCI individuals who underwent a third 18F-THK5351 PET scan 9–28 days after the selegiline administration, the SUV remained reduced (Fig. 3). There was no consistent regional 18F-THK5351 SUVR reduction in the post-selegiline scans from baseline (Figs. 3 and 4), which is in line with the anticipated differences in the PHF to MAO-B ratio in different brain regions of different participants, including the cerebellar cortex reference region.

14Autoradiography in postmortem brain sections of AD patients and healthy controls further demonstrated a reduction of total 18F-THK5351 uptake following 150 nM and 500 nM R--deprenyl hydrochloride challenge (Fig. 5a). This reduction was greater in the striatum, a region rich in MAO-B but with negligible PHF, than in the prefrontal cortex and hippocampus where both PHF and MAO-B are present (Fig. 5b).

15In summary, we showed that brain and cerebellar cortex MAO-B availability affects 18F-THK5351 SUV. Following a single 10 mg oral dose of selegiline, 18F-THK5351 SUVs decreased by approximately 30 to 50% depending on the brain region, with the highest decline noted in the basal ganglia and thalamus which are known to express the highest concentrations of MAO-B in the brain. The in vitro autoradiography blocking experiments showed similar effects. The long-lasting selegiline-evoked 18F-THK5351 SUV decline indicates MAO-B inhibition as the possible mechanism underlying this effect.

16MAO-B is a protein highly expressed in all brain regions. It is compartmentalized in the outer membrane of the astrocytes mitochondria. During the normal aging process, global MAO-B availability increases at the rate of nearly 9% per decade. In fact, MAO-B imaging has been proposed as a biomarker for astrocytosis in various neurodegenerative conditions associated with cell death or activation of immune responses, with some investigators reporting higher MAO-B binding in AD patients versus aged-matched controls. Moreover, MAO-B inhibition has significant therapeutic effects for mood disorders and Parkinson’s disease, and it is considered a therapeutic target for various neurodegenerative conditions.

17The high retention of tau imaging agents such as 18F-THK5351 and 18F-flortaucipir to brain structures known to be devoid of PHF has been attributed to off-target binding sites. It is important to emphasize that off-target binding implies specific (saturable) binding of the imaging agent to proteins other than the primary target for which it was intended. Generally, it is desirable that the affinity of the target binding sites be higher by at least one order of magnitude as compared to that of the off-target binding sites, although the lack of such a specificity might be acceptable if the target and off-target binding sites do not coexist in the same brain region. Our results suggest that 18F-THK5351 binds to MAO-B and PHF with similar affinity, which might be detrimental to PHF quantification in the brain. However, given that 18F-THK5351 is biochemically different from 18F-flortaucipir, our findings cannot be generalized.

18Interestingly, the acute selegiline challenge conducted in this study evoked the highest 18F-THK5351 SUV decline in the thalamus and striatum, which express high levels of MAO-B, and are also known to be devoid of PHF. However, it is worth mentioning that the magnitude of MAO-B inhibition in the aforementioned regions was variable, as described by previous studies. This variability can be attributed to individual differences in selegiline absorption, biodistribution, or pharmacodynamics. Furthermore, the exposure to MAO-B inhibitors present in tobacco, certain antidepressants, or herbal therapies may also influence such variability.

19The long-lasting effects of selegiline support MAO-B inhibition as the main mechanism involved in the effects observed by this study. Indeed, previous studies conducted in vivo estimate that the de novo synthesis half-life of MAO-B is 40 days. Our autoradiography results conducted in postmortem brain of AD patients (Fig. 5) also support 18F-THK5351 binding to both MAO-B and PHF. Importantly, the enrolment of a clinically heterogeneous population in this study was intended to test whether MAO-B availability affects 18F-THK5351 SUV independently of other specific pathophysiological processes.

20The selegiline challenge in the present study affected cortical 18F-THK5351 SUVs (Fig. 1) in regions known to accumulate PHF, such as the mesial basal temporal, temporal, and parietal cortices. These regions also express high concentrations of MAO-B. The visual assessments of 18F-THK5351 SUV images obtained in amyloid-positive individuals revealed the signature previously described in AD patients, which remained after the challenge with selegiline. Similarly, the high uptake in the midbrain and basal ganglia of our patient with PSP remained after the post-selegiline scan. This may support the concept that 18F-THK5351 binds to 4-R tau pathology in the midbrain and basal ganglia, which is consistent with the imaging signature recently described. The AD and PSP signatures observed after the selegiline challenge represent images with decreased effects of MAO-B availability.

21We found that cerebellar cortex 18F-THK5351 SUVs declined to a lesser extent as compared to cerebral cortical regions following the selegiline challenge. This observation is consistent with previous studies showing declines in cerebellar MAO-B availability following pharmacological inhibition. In our study, the quantification of 18F-THK5351 uptake using SUVR with the cerebellar cortex as a reference region was also sensitive to the selegiline challenge. Although cerebellar MAO-B availability invalidates the use of this region as a reference to derive 18F-THK5351 SUVR in the context of this study, future research should focus on methodology to correct MAO-B bias in 18F-THK5351 SUVR measurements.

22The use of imaging agents with low specificity is acceptable to analyze PET images from brain regions without off-target binding sites. However, the interpretation of PET data obtained using tracers with low specificity becomes challenging when target and off-target binding sites co-localize within specific anatomical regions. In this situation, the major issue is obtaining PET signals of interest without the confounding effects from off-target sites. Tracer specificity becomes even more important in the case of imaging agents targeting abnormal protein aggregates. At early stages of the disease, when the load of abnormal protein aggregates is negligible, as compared to the availability of off-target binding sites, one could expect a higher confounding signal from the off-target binding. By contrast, in later stages of the disease, the relative contribution of off-target binding is reduced given the higher concentrations of protein aggregates in the tissue, despite high concentrations of MAO-B in the hippocampus, temporal neocortex, and cingulate gyrus. It is also worth noting that the visual appearance of 18F-THK5351 PET images is not inconsistent with the pathological distribution of NFTs reported in Braak staging. The potential reason for this is that, as neurons are compromised by NFTs, astrocytosis ensues in these regions. The increase of MAO-B is likely due to astrocytosis in response to NFTs, and the PET signals here could be considered as a combination of both PHF and astrocytosis. This would need to be verified by future studies.

23The interpretation of these results should take into consideration the following methodological limitations. Firstly, the present study was not conducted using full dynamic scans with an arterial input function, but relied on the SUV measured on 18F-THK5351 images obtained from 50 to 70 min after tracer injection which is susceptible to physiological sources of variability. Secondly, although previous studies show that chronic administration of selegiline does not significantly affect cerebral blood flow, it has been reported that acute selegiline administration may induce rapid brain vasodilation via nitric oxide release. Hence, it is possible that the selegiline dose in the present study may induce cerebral blood flow changes and affect accurate quantification of 18F-THK5351 uptake.

24The present study supports the concept that MAO-B is an 18F-THK5351 off-target binding site. As such, the current methods for analyzing 18F-THK5351 inevitably incorporate undesired confounding signal from MAO-B availability, which probably dominates PET signals in early stages of AD. Therefore, it would be appropriate for the methods used to quantify 18F-THK5351 to take into account the cortical MAO-B signal. Importantly, heterogeneous MAO-B availability across the cortex may also limit the quantification of 18F-THK5351 uptake using reference brain regions. In addition, with regards to the use of 18F-THK5351 in longitudinal studies and clinical trials in AD, one should be aware that both MAO-B and tau binding may increase with age at different rates in different brain regions of different individuals, whilst tau binding will increase in the same fashion with disease progression, or potentially decrease in response to an efficacious treatment. As such, experiments should be designed and interpreted with care to account for these processes. Finally, it is important to emphasize that the confounding effect of MAO-B availability in patients with high loads of PHF should be further evaluated by subsequent studies.